Alterations in lipid transfers to HDL associated with the presence of coronary artery disease in patients with type 2 diabetes mellitus

Cardiovascular Diabetology

Volumn 14, Issue 1, 2015, Pages

  Sprandel, Marilia C O ^a   Hueb, Whady A ^a   Segre, Alexandre ^a   Ramires, José A F ^a   Kalil Filho, Roberto ^a   Maranhão, Raul C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cholesterol; Coronary artery disease; HDL; High density lipoprotein; Lipid transfers; Nanoparticles; Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNESTERIFIED CHOLESTEROL; APOB PROTEIN, HUMAN; APOLIPOPROTEIN B100; BIOLOGICAL MARKER; NANOPARTICLE;

ADULT; AGED; ARTICLE; BODY MASS; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL ESTERIFICATION; CHOLESTEROL TRANSPORT; CINEANGIOCARDIOGRAPHY; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; HUMAN; IN VITRO STUDY; INCUBATION TEMPERATURE; INCUBATION TIME; LIPID COMPOSITION; LIPID TRANSPORT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; PRECIPITATION; REVERSE CHOLESTEROL TRANSPORT; BLOOD; CINEANGIOGRAPHY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; MIDDLE AGED; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEIN B-100; BIOMARKERS; CASE-CONTROL STUDIES; CHOLESTEROL ESTERS; CHOLESTEROL, LDL; CINEANGIOGRAPHY; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; NANOPARTICLES; PARTICLE SIZE; RISK FACTORS;

EID: 84939162770     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-015-0270-8     Document Type: Article

References (37)

1. Pasterkamp G (2013) Methods of accelerated atherosclerosis in diabetic patients. Heart 99:743-749
2. Leança CC, Nunes VS, Panzoldo NB, Zago VS, Parra ES, Cazita PM et al (2013) Metabolism of plasma cholesterol and lipoprotein parameters are related to a higher degree of insulin sensitivity in high HDL-C healthy normal weight subjects. Cardiovasc Diabetol 12:173
3. Mooradian AD (2009) Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 5:150-159
4. Fruchart JC, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G et al (2014) Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol 13:26
5. Yassine HN, Belopolskaya A, Schall C, Stump CS, Lau SS, Reaven PD (2014) Enhanced cholesterol efflux to HDL through the ABCA1 transporter in hypertriglyceridemia of type 2 diabetes. Metabolism 63:727-734
6. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR (1977) High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62:707-714
7. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD et al (1989) High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79:8-15
8. Acharjee S, Boden WE, Hartigan PM, Teo KK, Maron DJ, Sedlis SP et al (2013) Low Levels of high density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: a post hoc analysis from the COURAGE Trial. J Am Coll Cardiol 62:1826-1833
9. Kontush A, Chapman MJ (2006) Functionally defective high-density lipoprotein: a newtherapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 58:342-374
10. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J et al (2012) Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 125:1905-1919
11. Tall A (1995) Plasma lipid transfer proteins. Ann Rev Biochem 64:235-257
12. Siebel AL, Natoli AK, Yap FY, Carey AL, Reddy-Luthmoodoo M, Sviridov D et al (2013) Effects of high-density lipoprotein elevation with cholesteryl ester transfer protein inhibition on insulin secretion. Circ Res 113:167-175
13. Abbasi A, Dallinga-Thie GM, Dullaart RP (2015) Phospholipid transfer protein activity and incident type 2 diabetes mellitus. Clin Chim Acta 439:38-41
14. Barter PJ, Rye KA (2012) Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J Lipid Res 53:1755-1766
15. Low H, Hoang A, Forbes J, Thomas M, Lyons JG, Nestel P et al (2012) Advanced glycation end-products (AGEs) and functionality of reverse cholesterol transport in patients with type 2 diabetes and in mouse models. Diabetologia 55:2513-2521
16. Lo Prete AC, Dina CH, Azevedo CH, Puk CG, Lopes NH, Hueb WA et al (2009) In vitro simultaneous transfer of lipids to HDL in coronary artery disease and in statin treatment. Lipids 44:917-924
17. Maranhao RC, Freitas FR (2014) HDL metabolism and atheroprotection: predictive value of lipid transfers. Adv Clin Chem 65:1-41
18. Maranhao RC, Freitas FR, Strunz CM, Santos RD, Mansur AJ, Mansur AP et al (2012) Lipid transfers to HDL are predictors of precocious clinical coronary heart disease. Clin Chim Acta 413:502-505
19. Hueb WA, Bellotti G, de Oliveira SA, Arie S, de Albuquerque CP, Jatene AD et al (1995) The Medicine, Angioplasty or Surgery Study (MASS): a prospective, randomized trial of medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenoses. J Am Coll Cardiol 26:1600-1605
20. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502
21. Lima E, Maranhão RC (2004) Rapid, simple laser-light scattering method for HDL particle size in whole plasma. Clin Chem 50:1086-1091
22. Bragdon JH, Eder HA, Gould RG, Havel RJ (1956) Lipid nomenclature: recommendations regarding the reporting of serum lipids and lipoproteins made by the Committee on Lipid and Lipoprotein Nomenclature of the American Society for the Study of Arteriosclerosis. Circ Res 4:129
23. Marotta T, Russo BF, Ferrara LA (2010) Triglyceride-to-HDL-cholesterol ratio and metabolic syndrome as contributors to cardiovascular risk in overweight patients. Obesity 18:1608-1613
24. Hermans MP, Ahn SA, Rousseau MF (2014) Novel unbiased equations to calculate triglyceride-rich lipoprotein cholesterol from routine non-fasting lipids. Cardiovasc Diabetol 13:56
25. Seviour PW, Teal TK, Richmond W, Elkeles RS (1988) Serum lipids, lipoproteins and macrovascular disease in non-insulin-dependent diabetics: a possible new approach to prevention. Diabet Med 5:166-171
26. Kahri J, Syvanne M, Taskinen MR (1994) Plasma cholesteryl ester transfer protein activity in non-insulin-dependent diabetic patients with and without coronary artery disease. Metabolism 43:1498-1502
27. Frohlich J, Dobiasova M (2003) Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. Clin Chem 49:1873-1880
28. Ng DS (2012) The role of lecithin: cholesterol acyltransferase in the modulation of cardiometabolic risks-a clinical update and emerging insights from animal models. Biochim Biophys Acta 1821:654-659
29. Savel J, Lafitte M, Pucheu Y, Pradeau V, Tabarin A, Couffinhal T (2012) Very low levels of HDL cholesterol and atherosclerosis, a variable relationship-a review of LCAT deficiency. Vasc Health Risk Manag 8:357-361
30. Rousset X, Shamburek R, Vaisman B, Amar M, Remaley AT (2011) Lecithin cholesterol acyltransferase: an anti- or pro-atherogenic factor? Curr Atheroscler Rep 13:249-256
31. Couto RD, Dallan LA, Lisboa LA, Mesquita CH, Vinagre CG, Maranhao RC (2007) Deposition of free cholesterol in the blood vessels of patients with coronary artery disease: a possible novel mechanism for atherogenesis. Lipids 42:411-418
32. Santos RD, Hueb W, Oliveira AA, Ramires JA, Maranhao RC (2003) Plasma kinetics of a cholesterol-rich emulsion in subjects with or without coronary artery disease. J Lipid Res 44:464-469
33. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K et al (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. New Eng J Med 364:127-135
34. Triolo M, Kwakernaak AJ, Perton FG, de Vries R, Dallinga-Thie GM, Dullaart RP et al (2013) Low normal thyroid function enhances plasma cholesteryl ester transfer in type 2 diabetes mellitus. Atherosclerosis 228:466-471
35. Dullaart RP, de Vries R, Dallinga-Thie GM, van Tol A, Sluiter WJ (2007) Plasma cholesteryl ester transfer protein mass and phospholipid transfer protein activity are associated with leptin in type 2 diabetes mellitus. Biochim Biophys Acta 1771:113-118
36. Inukai Y, Ito K, Hara K, Yamazaki A, Takebayashi K, Aso Y et al (2007) Serum cholesteryl ester transfer protein concentrations are associated with serum levels of total cholesterol, beta-lipoprotein and apoproteins in patients with type 2 diabetes mellitus. Med Princ Pract. 16:367-372
37. Morton RE (1988) Free cholesterol is a potent regulator of lipid transfer protein function. J Biol Chem 263:12235-12241